We employed the CRISPR/Cas9 genome editing platform for the generation of the desired targeted genomic rearrangement in the A549 lung cancer ... a dose-response based assay monitored via IncuCyte ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback